Polymyalgia rheumatica causes muscle pain and stiffness in the shoulders, hips, and neck, typically in people over 50. Most people respond quickly to corticosteroids, but many need treatment for one to two years. The challenge is reducing steroid dose without symptoms returning, and preventing complications like giant cell arteritis.
What's actually going on in research
Trials are testing steroid-sparing drugs that could reduce prednisone dependence, including tocilizumab (an IL-6 inhibitor already FDA-approved for giant cell arteritis) and methotrexate. Studies are also examining biomarkers that predict relapse, optimal tapering schedules, and whether early aggressive treatment leads to shorter overall steroid exposure.
Tocilizumab for steroid reduction
This IL-6 inhibitor helps many people reduce or stop prednisone. Studies are testing whether it works as initial therapy or only after steroids fail.
Biomarker studies
Researchers are looking for blood markers that predict who will relapse when tapering steroids. This could guide more personalized treatment schedules.
What to know before you search
Eligibility typically depends on disease duration, current prednisone dose, whether you've had relapses, and markers of inflammation like ESR or CRP.
What types of trials are currently open
- Steroid-sparing trials — Testing drugs like tocilizumab or methotrexate to see if they allow lower prednisone doses or faster tapering.
- Tapering strategy trials — Comparing different prednisone reduction schedules to find the approach that prevents relapse while minimizing steroid exposure.
- Prevention studies — Testing whether certain treatments reduce the risk of giant cell arteritis developing in people with polymyalgia rheumatica.
- Imaging studies — Using PET or ultrasound to understand inflammation patterns and predict who needs longer treatment.
- Long-term follow-up studies — Tracking people for years to understand disease patterns, relapse risk, and long-term effects of different treatments.
Recently added Polymyalgia Rheumatica trials
Share your health data to improve giant cell arteritis monitoring
Giant Cell Arteritis (GCA) is a vasculitis of medium- and large-sized arteries in older adults that may lead to serious vascular complications, including permanent vision loss and aortic aneurysm formation. Glucocorticoids are effective, but relapse during tapering is common and poses a major clinical challenge, potentially contributing to prolonged glucocorticoid exposure. Symptoms are often nonspecific and conventional inflammatory markers lack sufficient reliability, particularly in patients treated with drugs targeting the interleukin-6 pathway. Thus, this project aims to evaluate different tools assisting disease activity monitoring and/or predict future relapses and higher treatment requirements. Up to 175 patients with GCA in remission will be enrolled to ensure that 144 participants complete 1 year of follow-up. Participants undergo vascular ultrasonography, including double-blinded assessment at suspected relapse, complete patient-reported outcome measures, and provide biobank blood samples.
Take a new immune therapy with a steroid taper for polymyalgia rheumatica
This is a randomized, double-blind, placebo-controlled, parallel-group, Phase 4, 3-group study to assess whether treatment with sarilumab at either 150 mg q2w (once every two weeks) or at 200 mg q2w, each given with a 52-week prednisone taper, is superior to placebo given with a 52-week prednisone taper in participants with early polymyalgia rheumatica (PMR) and to determine the safety and tolerability of the sarilumab regimens. The study will consist of the following visits: Visit 1 (D-42 to D-1): Screening, Visit 2 (D1): Baseline, randomization, first study drug administration, Visit 3 to 12 (Week 2 to Week 52): Treatment period, Visit 13 (Week 52): End of Treatment (EOT) visit, Visit 14 (Week 58): End of Study (EOS) visit.
Find Polymyalgia Rheumatica trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.